MarketLens
Sign Up

What's Behind the Recent Insider Selling at AnaptysBio

6 months ago
SHARE THIS ON:

What's Behind the Recent Insider Selling at AnaptysBio

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News•2 days ago

Inhibrx's Insider Buying Adds Fuel to a High-Short-Interest Biotech Setup

Inhibrx Biosciences CEO bought over $3.6M of INBX shares after a clinical outperformance selloff, with ~28% of float short and an FDA approval date pending. The stock closed at $97.93, down 2.15% on 1...
Stock News•2 months ago

AnaptysBio: The Royalty Waterfall Is About To Reverse

AnaptysBio's value now hinges on Jemperli royalties from GSK, with a 95% targeted EBIT margin and over $140M net cash. Royalty retention will rise after the Sagard obligation is paid by mid-2027.
Stock News•2 months ago

What This MeiraGTx Insider Sale Might Mean With Two Drug Filings Near

MeiraGTx insider Stuart Naylor sold 27,659 shares for ~$409,000 at $14.80 each on July 7, reducing his direct holdings by 4%, ahead of two upcoming drug filings.

Breaking News

View All →

Top Headlines

View More →
Stock News•2 hours ago

Forget the S&P 500: SCHD Is Beating It by Nearly 10 Points in 2026 and Its Dividend Just Grew

Stock News•4 hours ago

NVDY: NVIDIA Shares Break To Record Highs, Don't Cede The Upside Now

Stock News•6 hours ago

Is Copilot Microsoft's Secret Weapon in the AI Arms Race?

Stock News•7 hours ago

2 Millionaire-Maker Quantum Computing Stocks to Buy Hand Over Fist

Stock News•7 hours ago

The AI Buildout Needs Power It Cannot Get: 4 Energy Stocks Already Have It